Waleed Mahmoud, DO
Family Medicine · Athens, TXNPI 1366447062
Payments from drug & device makers
Across 564 payments — averaging $16.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- AstraZeneca$960
- Boehringer Ingelheim$899
- Pfizer$760
- GSK$707
- Novo Nordisk$655
- plus $4K from 30 others
What the payments were for
- Food & beverage$9,228100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 71 | $1,187 |
| AstraZeneca | 54 | $960 |
| Boehringer Ingelheim | 57 | $899 |
| Pfizer | 42 | $760 |
| GSK | 51 | $707 |
| Novo Nordisk | 48 | $655 |
| Radius Health, Inc. | 30 | $538 |
| Mylan Specialty L.p. | 37 | $535 |
| Otsuka America Pharmaceutical, Inc. | 21 | $424 |
| Lilly USA, LLC | 21 | $326 |
| Bayer | 11 | $267 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $259 |
| Dexcom, Inc. | 12 | $214 |
| AbbVie(2 entities) | 10 | $173 |
| Kowa Pharmaceuticals America, Inc. | 10 | $162 |
| Novartis | 9 | $146 |
| Johnson & Johnson | 10 | $139 |
| Phathom Pharmaceuticals, Inc. | 6 | $122 |
| Amarin Pharma, Inc. | 5 | $105 |
| Nevro Corp. | 6 | $100 |
| Sunovion Pharmaceuticals Inc. | 8 | $75 |
| Genentech USA, Inc. | 4 | $75 |
| Merck | 5 | $74 |
| Axsome Therapeutics, Inc. | 3 | $60 |
| Antares Pharma, Inc. | 3 | $55 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $47 |
| Vanda Pharmaceuticals Inc. | 1 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Ironshore Pharmaceuticals Inc. | 1 | $18 |
| Ironwood Pharmaceuticals, Inc | 1 | $17 |
| Philips North America LLC | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Medtronic | 1 | $14 |
| Cranial Technologies, Inc | 1 | $13 |
| Shield Therapeutics Inc | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$125
How this compares
$9,228 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 104 | $155,573 |
| OzempicSemaglutide | 64 | $105,963 |
| Enbrel SureclickEtanercept | 13 | $95,388 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 98 | $81,030 |
| EliquisApixaban | 58 | $73,064 |
| XareltoRivaroxaban | 51 | $46,801 |
| FarxigaDapagliflozin Propanediol | 37 | $44,198 |
| MounjaroTirzepatide | 26 | $29,896 |
| EntrestoSacubitril/Valsartan | 13 | $16,342 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $12,086 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 27 | $11,696 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $9,723 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $9,534 |
| MyrbetriqMirabegron | 12 | $5,288 |
| Novolin NInsulin Nph Human Isophane | 33 | $5,182 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $899 | $155,573104 claims |
| Novo NordiskOzempic | $655 | $105,96364 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $707 | $92,726125 claims |
| PfizerEliquis, Paxlovid | $760 | $75,92374 claims |
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere | $960 | $66,00673 claims |
| Johnson & JohnsonXarelto | $139 | $46,80151 claims |
| Lilly USA, LLCMounjaro | $326 | $29,89626 claims |
| NovartisEntresto | $146 | $16,34213 claims |
| AbbVieSynthroid | $173 | $2,41062 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Athens
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.